GEP-NETs – Talk Bio

Actionable Insights Powered by AI

Sanofi Challenges Novartis’ Dominance with Clinically Meaningful Pancreatic Tumor Data from AlphaMedix Phase II Trial

2 weeks ago talkbio0Tagged AlphaMedix, gastroenteropancreatic neuroendocrine tumors, GEP-NETs, Novartis, Orano, Overall Survival, Phase 2 Clinical Trials, Progression-Free Survival, radioligand therapy, Radiopharma, safety profile, sanofi

Sanofi; Novartis; radiopharma; AlphaMedix; Orano Med; gastroenteropancreatic neuroendocrine tumors; GEP-NETs; radioligand therapy; Phase II clinical trial; progression-free survival; overall survival; safety profile

ITM’s Radiopharmaceutical ITM-11 Shows Promising Results in Phase III COMPOSE Trial for Advanced Neuroendocrine Tumors

9 months ago talkbio0Tagged COMPOSE trial, GEP-NETs, ITM-11, Neoplasms, Neurosecretory Systems, Radionuclide therapy

ITM-11, neuroendocrine tumors, GEP-NETs, COMPOSE trial, targeted radionuclide therapy, 177Lu-edotreotide